GMAB News and Press, Genmab A/S From 12/09/23

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) PR Newswire - Data from Phase 1/2 EPCORE™ NHL-1 study show patients tre...

2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares  ( HBANL ) +3% . Genmab  ( GMAB ) +3% . Losers: Fluence En...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-11-27 08:03:06 ET More on AbbVie, Genmab, etc. AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript Genmab A/S 2023 Q3 - Results - Earnings Call Presentation AbbVie suing Sandoz, four others to block ...

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy European Medicines Agency (EMA) validates regulatory applicatio...

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 8, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has inform...

2023-11-07 17:19:08 ET More on Genmab Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript Genmab A/S 2023 Q3 - Results - Earnings Call Presentation Genmab Is Down To Attractive Levels Seagen, Genmab update Phase 3 data for uterine cancer therapy Genmab...

2023-11-07 14:32:09 ET Genmab A/S (GMAB) Q3 2023 Earnings Conference Call November 07, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & Chief Executive Officer Anthony Pagano - Executive Vice President & Chief Financial Office...

November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY ® ) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or re...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...